Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | PHGDH | O43175 | 6/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
| ▸ | NMT1 | P30419 | 1/20 | 0.30 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL962752 | 0.92 | PTGDR2 (0.31) | PTGDR2PHGDHLMNAOXER1 | |
| SCHEMBL964535 | 0.90 | OXER1 (0.33) | PTGDR2LMNAOXER1 | |
| SCHEMBL967888 | 0.90 | MAPK8 (0.34) | PTGDR2PHGDHLMNAMAPK8MAPK9 | |
| SCHEMBL966868 | 0.88 | SLC6A2 (0.35) | PTGDR2PHGDHLMNAMAPK8MAPK9 | |
| SCHEMBL967867 | 0.87 | PHGDH (0.35) | PTGDR2PHGDHLMNAMAPK8 | |
| SCHEMBL963395 | 0.87 | KMT2A (0.37) | PTGDR2PHGDH | |
| SCHEMBL965057 | 0.87 | PTGDR2 (0.34) | PTGDR2PHGDHLMNAMAPK8MAPK9 | |
| SCHEMBL962091 | 0.86 | PHGDH (0.34) | PTGDR2PHGDHLMNAMAPK8 | |
| SCHEMBL964464 | 0.86 | NPY5R (0.35) | PTGDR2PHGDHLMNAMAPK8MAPK9 | |
| SCHEMBL966069 | 0.83 | OXER1 (0.34) | PTGDR2LMNAMAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | PTGDR2 295/4885PHGDH 1142/4885LMNA 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.